World Journal of Otorhinolaryngology-Head and Neck Surgery, 2022 Background PD‐1 and PD‐L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC). Methods Systematic review and meta‐analysis of PD‐1 and PD‐L1 inhibitors in HNSCC.
Dylan A. Levy +9 more
doaj +1 more source
Tolerance without clonal expansion: Self-antigen-expressing B cells program self-reactive T cells for future deletion [PDF]
, 2008 B cells have been shown in various animal models to induce immunological tolerance leading to reduced immune responses and protection from autoimmunity.
Anderton, Stephen M. +9 more
core +1 more source
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]
, 2016 A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R +11 more
core +2 more sources
In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
Frontiers in Cellular and Infection Microbiology, 2019 In the present study, we determined the in vitro characteristics and binding interactions of chicken PD-1 (chPD-1) and PD-L1 (chPD-L1) and developed a panel of specific monoclonal antibodies against the two proteins.
Vishwanatha R. A. P. Reddy +3 more
doaj +1 more source
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? [PDF]
, 2019 Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent.
Badalamenti G. +11 more
core +1 more source
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. [PDF]
, 2020 PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.
Algazi, Alain P +23 more
core +2 more sources
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]
, 2016 BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas +11 more
core +2 more sources
A structural study of a C3H3 species coadsorbed with CO on Pd(1 1 1) [PDF]
, 2008 The combination of chemical-state-specific C 1s scanned-energy mode photoelectron diffraction (PhD) and O K-edge near-edge X-ray absorption fine structure (NEXAFS) has been used to determine the local adsorption geometry of the coadsorbed C3H3 and CO ...
Allegretti, F. +5 more
core +1 more source
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]
, 2020 Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin +13 more
core +1 more source
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
BMC Cancer, 2020 Background There are many types of therapies for cancer. In these days, immunotherapies, especially immune checkpoint inhibitors, are focused on. Though many types of immune checkpoint inhibitors are there, the difference of effect and its mechanism are ...
Kazushige Yoshida +15 more
doaj +1 more source